Naveen Pemmaraju: Our new report on DDX for mediastinal mass in patient with B-ALL
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by him and colleagues published in Journal of Immunotherapy and Precision Oncology:
“Delighted to share our new report led by our superstar Resident MD Dr. Luan Phan in Journal of Immunotherapy and Precision Oncology! DDX for mediastinal mass in patient with B-ALL.”
“Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic Leukemia”
Authors: Luan Phan, Elias Jabbour, Mara Antonoff, Nitin Jain, Pei Lin, Cesar Moran, Naveen Pemmaraju.
More posts featuring Naveen Pemmaraju.
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023